The Technical Analyst
VBI Vaccines Inc [VBIV]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
VBI Vaccines Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.91% $0.609
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 17.30 mill |
| EPS: | -6.03 |
| P/E: | -0.100 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 28.43 mill |
| Avg Daily Volume: | 0.463 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.100 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.100 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.559 - 0.659 ( +/- 8.22%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-07-27 | Dewilde Michel | Buy | 35 000 | Option (Right to Buy Common Shares) |
| 2023-07-27 | Braga Damian | Buy | 35 000 | Option (Right to Buy Common Shares) |
| 2023-07-27 | Baxter Jeff | Buy | 70 000 | Option (Right to Buy Common Shares) |
| 2023-07-27 | Cordeiro Joanne | Buy | 35 000 | Option (Right to Buy Common Shares) |
| 2023-07-27 | Beattie Nell | Buy | 52 500 | Option (Right to Buy Common Shares) |
| INSIDER POWER |
|---|
| -68.19 |
| Last 96 transactions |
| Buy: 56 847 323 | Sell: 16 390 901 |
Forecast:
16:00 - $0.608
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.608
Forecast 2: 16:00 - $0.608
Forecast 3: 16:00 - $0.608
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.609 (0.91% ) |
| Volume | 0.113 mill |
| Avg. Vol. | 0.463 mill |
| % of Avg. Vol | 24.52 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VBIV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VBIV
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-16 08:00:00 - Press Release
Vbi Vaccines Reports Full Year 2023 Financial Results
Cambridge, mass.--(business wire)--vbi vaccines inc. (nasdaq: vbiv) (vbi), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended december 31, 2023. “over the last 12 months, we've seen continued progress across all of our lead programs – with increased use of prehevbrio and an ever-expanding access and distribution network in place, as well as positive c.
2024-04-11 16:05:00 - Press Release
Vbi Vaccines Announces Closing Of $2 Million Registered Direct Offering Priced At-the-market Under Nasdaq Rules
Cambridge, mass.--(business wire)--vbi vaccines inc. (nasdaq: vbiv) (vbi), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the closing of its previously announced registered direct offering priced at-the-market under nasdaq rules of 2,272,728 of its common shares and warrants to purchase up to 2,272,728 common shares, at an offering price of $0.88 per common share and associated warrant. the warrants have an exerci.
2024-04-09 14:45:00 - Press Release
Vbi Vaccines Announces $2 Million Registered Direct Offering Priced At-the-market Under Nasdaq Rules
Cambridge, mass.--(business wire)--vbi vaccines inc. (nasdaq: vbiv) (vbi), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has entered into definitive agreements for the sale and issuance of 2,272,728 common shares (or pre-funded warrants in lieu thereof) of vbi at an offering price of $0.88 per common share (or per pre-funded warrant in lieu thereof), in a registered direct offering priced at-the-market un.
2024-04-03 08:00:00 - Press Release
Vbi Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study Of Vbi-1901 In Recurrent Glioblastoma
Cambridge, mass.--(business wire)--vbi vaccines inc. (nasdaq: vbiv) (vbi), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that david e. anderson, ph.d., vbi's chief scientific officer, will present early tumor response data from the ongoing phase 2b study of vbi-1901, vbi's cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (rgbm) at the world vaccine congress washington at 1:10pm et on april 3,.
2024-04-02 08:00:00 - Press Release
Vbi Vaccines Announces Expanded Strategic Partnership With Canadian Government To Advance Mrna-launched Evlp (mle) Vaccine Platform
Cambridge, mass.--(business wire)--vbi vaccines inc. (nasdaq: vbiv) (“vbi” or the “company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has expanded its collaboration with the government of canada, supported by a funding contribution from the government's strategic innovation fund (sif). under the new agreement, the remaining cad$28 million of funding available under the previously committed cad$56 mi.
Latest News
2023-09-27 07:49:00 - Market Watch
VBI Vaccines' pan-coronavirus vaccine candidate produced broad protection against variants of concern
VBI Vaccines Inc. said Wednesday the first clinical data from a Phase I trial of a pan-coronavirus vaccine candidate produced broad and durable protection against variants of concern.
2023-07-06 09:05:36 - InvestorPlace
Why Is VBI Vaccines (VBIV) Stock Down 40% Today?
VBI Vaccines (NASDAQ: VBIV ) stock is taking a beating on Thursday after the pharmaceutical company announced two stock offerings. VBI Vaccines announced both a public stock offering and a registered directing offering for shares of VBIV stock.
2023-05-15 10:41:21 - Zacks Investment Research
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates
VBI Vaccines, Inc. (VBIV) came out with a quarterly loss of $2.43 per share versus the Zacks Consensus Estimate of a loss of $2.27. This compares to loss of $2.40 per share a year ago.
2023-04-05 12:56:14 - Zacks Investment Research
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.
2023-04-04 08:14:00 - Market Watch
VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split
VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct a reverse stock split. Cambridge, Mass.
2023-03-13 10:44:35 - Zacks Investment Research
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-10-13 12:48:20 - Zacks Investment Research
VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study
VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.
2022-09-22 10:42:50 - Seeking Alpha
VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook
VBI Vaccines has not been immune to sell-off with their share price shrinking by roughly 75% over the past year despite the company making significant headway both clinically and commercially. VBIV is still in my Compounding Healthcare "Bio Boom" speculative portfolio. The company's efforts in 2022 have fortified that position.
2022-08-27 03:44:08 - Pulse2
VBI Vaccines (VBIV) Stock: Why It Fell 10.72% After Hours
The stock price of VBI Vaccines (VBIV) fell by 10.72% after hours in the most recent trading session. This is why.
2022-07-14 12:30:55 - The Motley Fool
Why Ocugen, Sorrento Therapeutics, and VBI Vaccines Are on the Move Today
